A New Class of Therapy for Obstructive Sleep Apnea: Hypoglos
In early 2014, the FDA approved a new category of therapy for OSA: hypoglossal nerve stimulation. This stimulation is delivered by implantation of the Inspire® Upper Airway Stimulation device. The device includes a programmable neurostimulator, a stimulation lead to the hypoglossal nerve and a pressure-sensing lead that detects respiration. The effect of the stimulation is to protrude the tongue forward and open the pharyngeal airway during respiration.

A pivotal trial recently demonstrated the safety and efficacy of Inspire therapy in a subset of patients with moderate to severe OSA. The investigators reported that the mean reduction in the apnea-hypopnea index (AHI) was 68 percent...